<PAGE>
FOR IMMEDIATE RELEASE
Contact: Paul Knopick
714-545-0100 ext. 2465
SCHERING-PLOUGH LICENSES
ORAL ANDROGEN TO SPI PHARMACEUTICALS
COSTA MESA, Calif., Jan. 10, 1994 -- SPI Pharmaceuticals, Inc.
(AMEX:SPI) and Schering-Plough Corporation have announced an
agreement in which SPI will be the exclusive licensee in the U.S.
and Puerto Rico of the Oreton Methyl Line (brand of
methyltestosterone tablets, USP), a prescription oral androgen to
be manufactured by Schering-Plough.
The product will be marketed by SPI Pharmaceuticals under the ICN
Pharmaceuticals label as Oreton Methyl 10 (10mg), under the
agreement which became effective January 1, 1994. The product is
professionally marketed to physicians.
Oral androgens are intended for use by males as a replacement
therapy in conditions associated with a deficiency or absence of
testosterone (hypogonadism). They also are a second line therapy
for advanced, inoperable metastatic (skeletal) breast cancer for
women who are one to five years post-menopausal.
SPI Pharmaceuticals (AMEX:SPI), headquartered in Costa Mesa,
Calif., manufactures, markets and distributes more than 600
prescription and nonprescription pharmaceuticals in over 60
countries, including North and Latin America, Western and Eastern
Europe and the Far East.
Schering-Plough Corporation, based in Madison, NJ, is a research-
based company engaged in the discovery, development, manufacturing
and marketing of pharmaceutical and health care products worldwide.
Terms of the transaction were not disclosed.
